Celldex Therapeutics Inc（CLDX）股票分析CLDXCelldex Therapeutics Inc

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Celldex Therapeutics Inc is a good buy right now due to its current price of $29.25, which is significantly lower than the analyst price target of $64, indicating a potential upside of 118%. Additionally, the stock has shown a positive 5-day change of +6.25%, reflecting recent bullish sentiment following successful Phase 3 trial results for its drug Barzolvolimab. However, the main risk is the company's negative net income, which reached -78,685,000 USD in Q1 2026, highlighting ongoing financial challenges.

7 analysts cover CLDX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 55.00.